# Instylla

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/instylla

- Industry: Medical Devices & Equipment
- Headquarters: Bedford, US
- Website: www.instylla.com
- Total disclosed funding: $55M
- Latest round: Series B (Aug 8, 2023)
- Investors on record: 7

## About

Based in the US, Instylla, Inc. operates as a medical technology company specializing in next-generation liquid embolics for interventional radiology, focusing on effective solutions for oncology and vascular treatments.Instylla, Inc. was founded in 2017 and is headquartered in Bedford, US. The company focuses on developing innovative solutions in interventional radiology. In August 2023, Instylla raised USD 30.03 mn in Series B funding led by Delos Capital Partners, with participation from AMED Ventures, Ascension Ventures, Catalyst Health Ventures, Excelestar Ventures, Incept, and Sparta Group. The total amount raised to date is USD 30.03 mn, leading to a current company valuation of USD 131.628 mn.Instylla, Inc. specializes in the development of next-generation liquid embolics for applications in interventional radiology, with core products including the Embrace Hydrogel Embolic System and the Tembo Embolic System. These products aim to provide precise delivery of embolic agents to occlude blood vessels, addressing critical medical conditions such as tumors and bleeding. Instylla’s offerings cater primarily to hospitals and healthcare providers in North America and Europe, focusing on advanced interventional therapies.Instylla operates on a business-to-business (B2B) model, generating revenue through direct sales of its embolic systems via supply agreements and contracts with healthcare organizations. The Embrace Hydrogel Embolic System and the Tembo Embolic System are central to its revenue strategy, with bulk orders from healthcare facilities integrating these products into their interventional practices. Specific pricing and transaction volumes are proprietary and negotiated with healthcare partners.In August 2023, Instylla, Inc. raised USD 30.3 mn in Series B funding, led by Delos Capital Partners with contributions from several other investors. This funding will be utilized to support the commercialization and clinical testing of its product. Plans are underway to launch new products designed for the interventional radiology market and expand into additional geographic regions, particularly in Europe and Asia, by 2024.

## Funding rounds

- Series B, Aug 8, 2023, $30M — Catalyst Health Ventures, Ascension Ventures, Sparta Group, Excelestar Ventures, Delos Capital Partners, Incept, AMED Ventures
- Series B, Oct 6, 2020, $25M — Catalyst Health Ventures, Ascension Ventures, Excelestar Ventures, Sparta Group, Incept, AMED Ventures

## Investors

- Catalyst Health Ventures (https://capitalatlas.ai/funds/catalyst-health-ventures) — Series B
- Ascension Ventures (https://capitalatlas.ai/funds/ascension-ventures) — Series B
- Excelestar Ventures (https://capitalatlas.ai/funds/excelestar-ventures) — Series B
- Sparta Group — Series B
- Incept (https://capitalatlas.ai/funds/incept) — Series B
- AMED Ventures (https://capitalatlas.ai/funds/amed-ventures) — Series B
- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series B